Revolutionizing Liver Care with AI
Multimodal AI for Early Detection of Fatty Liver Disease
Global Impact & Market Opportunity
Addressing one of the world's most pressing healthcare challenges with cutting-edge AI technology
Over 1.5 billion people affected by fatty liver disease globally, with numbers rising annually
Of patients with fatty liver disease are unaware of their condition until advanced stages
Annual increase in fatty liver disease cases, with 5% and 10% respectively from 1990-2019
U.S. Liver Disease Burden & Financial Savings
Prevalence & Spend
- • NAFLD (MASLD): 80-100M adults (30-40% prevalence)
- • NASH (MASH): 16-20M adults (6-8% prevalence)
- • Cirrhosis: 4.5-6.2M adults (1.8-2.5% prevalence)
- • HCC: 42K new cases annually - $8B for liver transplantation
Potential Savings with Early Detection
- • $2 per 1000 patients (cost-effective)
- • 10% cost reduction in liver disease management
- • 1M patient population - $100K cost annual savings
- • HCC: Early risk 20% reduction - $1.6B cost annual savings
Strategic Takeaway: AI-enabled early detection is not just medically critical - it's financially transformative, offering substantial cost savings while improving patient outcomes.
Karyon Bio Solution
Generative digital twin of the liver
That fuses multi-omics + imaging (US/MRI) + longitudinal EHR
Predict progression from disease to fibrosis, + complex other comorbidities
Personalized treatment recommendations
Seamlessly integrate with existing clinical workflows and EHR systems
Deployment ready to reference cloud
Early Outcomes
Why Early Detection is Critical
LiverTwin Platform: Technical Architecture
Enterprise-grade AI platform built for scalability, security, and clinical integration
Integrates imaging, genomics, clinical data, and longitudinal EHR records
Advanced machine learning models for disease progression prediction
Scalable, HIPAA-compliant cloud deployment with global accessibility
Enterprise-grade security with full regulatory compliance
Why Invest in Karyon Bio
Strategic advantages that position Karyon Bio as a compelling investment opportunity in the rapidly growing AI healthcare market
Validated Partnerships & Pilots
Proven market validation through strategic partnerships and successful pilot programs with leading healthcare institutions.
Phased SaaS Adoption
Scalable revenue model with structured SaaS implementation phases ensuring sustainable growth and customer retention.
Defensible IP & Scientific Depth
Strong intellectual property portfolio backed by rigorous scientific research and University of Liverpool expertise.
Global Reach & Joint Branding
International expansion opportunities with prestigious university branding and established global healthcare networks.
US Revenue Plan: $72M ARR by 2030
Start with regulatory wedge, prove workflow ROI, unlock reimbursement momentum, and scale via enterprise hospital deals, payer cost-offset contracts, and pharma recruitment
Three Revenue Streams
AI risk flagging from EHR + imaging, one-tap elastography order, team coordination, referral tracking, ROI dashboard
High-NPV rule-outs, targeted elastography pathways, claims-linked savings analytics
Automated trial candidate identification and site activation for MASLD/MASH and fibrosis studies
5-Year Revenue Forecast
| Year | Hospitals | Payers | Pharma/CRO | Total ARR |
|---|---|---|---|---|
| 2026 | $1.3M | $0.3M | $1.2M | $2.8M |
| 2027 | $5.2M | $1.8M | $3.6M | $10.6M |
| 2028 | $11.7M | $4.8M | $7.0M | $23.5M |
| 2029 | $22.4M | $10.0M | $12.0M | $44.4M |
| 2030 | $36.0M | $18.0M | $18.0M | $72.0M |
Unit Economics
Workflow > Model: Own the care pathway (alerts, orders, team coordination, transfer/tele-hepatology)
Payment Early: Build studies that make coverage straightforward; codes follow outcomes
Footprint Compounds: Every new site increases trial recruitment reach and payer proof—flywheel across all three revenue lanes
Acceleration Capital: Complete De Novo/510(k) submission, multi-site US pilots, and Cat III CPT dossier
Global Clinical Network: Extend LiverTwin™ evidence and recruitment reach while we monetize the US market
Multi-Domain Expert Team
World-class expertise spanning AI research, clinical medicine, and healthcare technology
Leading researchers from University of Liverpool and top global institutions
Board-certified hepatologists and gastroenterologists with decades of experience
Former executives and engineers from leading healthcare technology companies
Multi-Domain Expert Team
Our world-class team combines decades of expertise in AI, biomedical research, and healthcare innovation
Srinivas Thirunagari
Founder & CEO
25+ Years in AI and Computer Vision. Seasoned entrepreneur – led or been part of four startups
Amandeep Singh
VP - Strategy and Operations
PhD – IISc, Bangalore, India. 8+ Years Business Development
Eckart Bindewald
Chief Scientific Officer
PhD – University of Heidelberg. 20+ Years in AI/ML for biomedical research
Dhatchana Moorthy
Principal Scientist - Biomarker
PhD – University of Madras, India. 25+ Years in Pre-clinical & Genomics
Mahati Munikoti
Sr. Research Scientist Bioinformatics
MS – Indiana University Bloomington. 7+ Years in Bioinformatics & AI/ML
Bing Betty Wei
Chief Growth Officer
PG – Harvard Business School. 20+ Years Corporate Governance & Business Development
Our Advisors
Distinguished medical professionals and scientists guiding our clinical development
Gourab Bagchi
Gastroenterologist & Hepatologist
MD – SGPGIMS, Lucknow. 15+ Years Distinguished gastroenterologist
Undurti Das
Physician & Scientist
MD, DSc – Osmania Medical College. 40+ Years as Physician & Scientist
Rami Reddy Yalaka
Gastroenterologist & Hepatologist
MD – PGIMER, Chandigarh. 15+ Years as Interventional Gastroenterologist
Aleem Mohammed
Digital Pathologist
MD – Christian Medical College, Vellore. 7+ Years as Digital Pathologist, Cytogenetics
Partner With Us
Join us in revolutionizing liver care and creating significant value for patients and investors
Get in Touch
Mountain View, CA 94043, USA